Understanding CXXC1P1: A Potential Drug Target and Biomarker (G392459)

Target Name: CXXC1P1

NCBI ID: G392459

CXXC1P1

Other Name(s): NCRNA00236 | CXorf25 | CXXC finger protein 1 pseudogene 1

Understanding CXXC1P1: A Potential Drug Target and Biomarker

CXXC1P1, also known as NCRNA00236, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and subcellular localization in the nucleus have made it an attractive target for researchers to study and develop new therapeutic approaches.

CXXC1P1 is a 22-kDa RNA molecule that is expressed in most tissues of the body. It is highly conserved in its sequence, with only a minor difference between the 5' and 3' ends. The molecule has a unique feature at its 3' end, a double-stranded RNA loop that is highly conserved in many organisms and is known as the \"T-loop.\" This loop is thought to play a role in the stability and localization of the molecule in the nucleus.

One of the reasons why CXXC1P1 has generated so much interest is its subcellular localization in the nucleus. The nucleus is a highly condensed and organized structure in the cell, and it is home to many important genetic and regulatory molecules. However, the nucleus is also a difficult target for drugs, as many drugs have been shown to be membrane-permeable and cannot penetrate the nucleus.

CXXC1P1 has been shown to be highly localized to the nucleus, with a subcellular localization of 80-90% in the nuclei of HeLa cells. This localization is consistent with the idea that the molecule is designed to interact with and be retained within the nucleus.

In addition to its subcellular localization, CXXC1P1 has also been shown to have important functions in various cellular processes. For example, it has been shown to be involved in the regulation of gene expression, specifically in the RNA polymerase II (RNA-protein interactions) pathway. This pathway is important for the production of proteins from mRNA templates, and it is a well-established target for drugs that inhibit protein synthesis.

CXXC1P1 has also been shown to be involved in the regulation of cellular processes related to cell adhesion and migration. It has been shown to interact with the protein known as E-cadherin, which is a transmembrane protein that is involved in cell-cell adhesion. This interaction between CXXC1P1 and E-cadherin suggests that the molecule may be involved in the regulation of cell-cell adhesion, which is important for various cellular processes, including tissue repair and regeneration.

Furthermore, CXXC1P1 has also been shown to be involved in the regulation of cell apoptosis, a process that is important for the elimination of damaged or dysfunctional cells. The T-loop region of the CXXC1P1 molecule has been shown to play a role in the regulation of apoptosis, and it is thought to interact with the protein known as Bcl-2. Bcl-2 is a protein that has been shown to play a role in the regulation of apoptosis, and it is a potential drug target for various diseases.

In conclusion, CXXC1P1 is a unique and highly interesting molecule that has generated a lot of interest in the scientific community. Its subcellular localization in the nucleus and its functions in various cellular processes make it a potential drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the role of CXXC1P1 in the regulation of cellular processes and its potential as a therapeutic approach.

Protein Name: CXXC Finger Protein 1 Pseudogene 1

The "CXXC1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CXXC1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets